IMPACT SCORE JOURNAL RANKING CONFERENCE RANKING Conferences Journals Workshops Seminars SYMPOSIUMS MEETINGS BLOG LaTeX 5G Tutorial Free Tools

Search About Journals, Conferences, and Book Series

Endocrine, Metabolic and Immune Disorders - Drug Targets- Impact Score, Overall Ranking, h-index, SJR, Rating, Publisher, ISSN, and Other Important Metrics

Last Updated on May 27, 2022

Impact Score

2.31

h-Index

 55

Rank

 10190

SJR

 0.49

Note: The impact score shown here is equivalent to the average number of times documents published in a journal/conference in the past two years have been cited in the current year (i.e., Cites / Doc. (2 years)). It is based on Scopus data and can be a little higher or different compared to the impact factor (IF) produced by Journal Citation Report. Please refer to the Web of Science data source to check the exact journal impact factor ™ (Thomson Reuters) metric.

Important Metrics

Title Endocrine, Metabolic and Immune Disorders - Drug Targets
Abbreviation Endocr. Metab. Immune Disord. - Drug Targets
Publication Type Journal
Subject Area, Categories, Scope Endocrinology, Diabetes and Metabolism (Q3); Immunology and Allergy (Q3)
h-index 55
Overall Rank/Ranking 10190
SCImago Journal Rank (SJR) 0.49
Impact Score 2.31
Publisher Bentham Science Publishers B.V.
Country United Arab Emirates
ISSN 18715303




About Endocrine, Metabolic and Immune Disorders - Drug Targets


Endocrine, Metabolic and Immune Disorders - Drug Targets is a journal covering the technologies/fields/categories related to Endocrinology, Diabetes and Metabolism (Q3); Immunology and Allergy (Q3). It is published by Bentham Science Publishers B.V.. The overall rank of Endocrine, Metabolic and Immune Disorders - Drug Targets is 10190. According to SCImago Journal Rank (SJR), this journal is ranked 0.49. SCImago Journal Rank is an indicator, which measures the scientific influence of journals. It considers the number of citations received by a journal and the importance of the journals from where these citations come. SJR acts as an alternative to the Journal Impact Factor (or an average number of citations received in last 2 years). This journal has an h-index of 55. The best quartile for this journal is Q3.

The ISSN of Endocrine, Metabolic and Immune Disorders - Drug Targets journal is 18715303. An International Standard Serial Number (ISSN) is a unique code of 8 digits. It is used for the recognition of journals, newspapers, periodicals, and magazines in all kind of forms, be it print-media or electronic. Endocrine, Metabolic and Immune Disorders - Drug Targets is cited by a total of 997 articles during the last 3 years (Preceding 2021).


Endocrine, Metabolic and Immune Disorders - Drug Targets Impact Score 2021-2022


The impact score (IS) 2021 of Endocrine, Metabolic and Immune Disorders - Drug Targets is 2.31, which is computed in 2022 as per its definition. Endocrine, Metabolic and Immune Disorders - Drug Targets IS is decreased by a factor of 0.37 and approximate percentage change is -13.81% when compared to preceding year 2020, which shows a falling trend. The impact score (IS), also denoted as Journal impact score (JIS), of an academic journal is a measure of the yearly average number of citations to recent articles published in that journal. It is based on Scopus data.

Table Setting

Endocrine, Metabolic and Immune Disorders - Drug Targets Impact Score 2022 Prediction


IS 2021 of Endocrine, Metabolic and Immune Disorders - Drug Targets is 2.31. If the same downward trend persists, impact score may fall in 2022 as well.


Impact Score Trend


Year wise Impact Score (IS) of Endocrine, Metabolic and Immune Disorders - Drug Targets. Based on Scopus data.


Year Impact Score (IS)
2022/2023 Coming Soon
2021 2.31
2020 2.68
2019 1.97
2018 1.27
2017 2.02
2016 2.23
2015 2.04
2014 1.77

Endocrine, Metabolic and Immune Disorders - Drug Targets h-index


  Table Setting

Endocrine, Metabolic and Immune Disorders - Drug Targets has an h-index of 55. It means 55 articles of this journal have more than 55 number of citations. The h-index is a way of measuring the productivity and citation impact of the publications. The h-index is defined as the maximum value of h such that the given journal/author has published h papers that have each been cited at least h number of times.




Endocrine, Metabolic and Immune Disorders - Drug Targets ISSN


The ISSN of Endocrine, Metabolic and Immune Disorders - Drug Targets is 18715303. ISSN stands for International Standard Serial Number.

An ISSN is a unique code of 8 digits. It is used for the recognition of journals, newspapers, periodicals, and magazines in all kind of forms, be it print-media or electronic.

Table Setting

Endocrine, Metabolic and Immune Disorders - Drug Targets Rank and SCImago Journal Rank (SJR)


The overall rank of Endocrine, Metabolic and Immune Disorders - Drug Targets is 10190. According to SCImago Journal Rank (SJR), this journal is ranked 0.49. SCImago Journal Rank is an indicator, which measures the scientific influence of journals. It considers the number of citations received by a journal and the importance of the journals from where these citations come.


Endocrine, Metabolic and Immune Disorders - Drug Targets Publisher


Table Setting

Endocrine, Metabolic and Immune Disorders - Drug Targets is published by Bentham Science Publishers B.V.. It's publishing house is located in United Arab Emirates. Coverage history of this journal is as following: 2006-2021. The organization or individual who handles the printing and distribution of printed or digital publications is known as Publisher.


Call For Papers


Visit the official website of the journal/conference to check the further details about the call for papers.


Abbreviation


The IS0 4 standard abbreviation of Endocrine, Metabolic and Immune Disorders - Drug Targets is Endocr. Metab. Immune Disord. - Drug Targets. This abbreviation ('Endocr. Metab. Immune Disord. - Drug Targets') is well recommended and approved for the purpose of indexing, abstraction, referencing and citing goals. It meets all the essential criteria of ISO 4 standard.

ISO 4 (International Organization for Standardization 4) is an international standard that defines a uniform and consistent system for abbreviating serial publication titles and journals.


How to publish in Endocrine, Metabolic and Immune Disorders - Drug Targets


If your research field is/are related to Endocrinology, Diabetes and Metabolism (Q3); Immunology and Allergy (Q3), then please visit the official website of this journal.


Acceptance Rate


The acceptance rate/percentage of any academic journal/conference depends upon many parameters. Some of the critical parameters are listed below.

  • The demand or interest of researchers/scientists in publishing in a specific Journal/Conference.
  • Peer review complexity and timeline.
  • The mix of unsolicited and invited submissions.
  • The time it takes from manuscript submission to final publication.
  • And Many More.

It is essential to understand that the acceptance rate/rejection rate of papers varies among journals. Some Journals considers all the manuscripts submissions as a basis of acceptance rate computation. On the other hand, few consider the only manuscripts sent for peer review or few even not bother about the accurate maintenance of total submissions. Hence, it can provide a rough estimation only.

The best way to find out the acceptance rate is to reach out to the associated editor or to check the official website of the Journal/Conference.


Credits and Sources


  • Scimago Journal & Country Rank (SJR), https://www.scimagojr.com/
  • Journal Impact Factor, https://clarivate.com/



Impact Score, h-Index, and Other Important Details of These Journals, Conferences, and Books


Journal/Conference/Workshop/Book Title Type Ranking Publisher h-index Impact Score
Journal of Babol University of Medical Sciences journal 21761 Babol University of Medical Sciences 16 0.35
Security Dialogue journal 3155 SAGE Publications Ltd 75 3.38
Journal of Mechanics of Materials and Structures journal 13051 Mathematical Sciences Publishers 44 1.74
Southwestern Historical Quarterly journal 26398 University of Texas Press 7 0.04
EuroIntervention journal 1720 EuroPCR 82 3.26
Sound and Vibration trade journal 20331 Tech Science Press 34 0.50
Journal of Laser Micro Nanoengineering journal 15043 Japan Laser Processing 28 1.30
Acta Obstetricia et Gynecologica Scandinavica journal 2923 Wiley-Blackwell 106 3.79
Turkish Journal of Mathematics journal 10729 TUBITAK 29 0.95
Chemometrics and Intelligent Laboratory Systems journal 6445 Elsevier 132 4.22

Check complete list




Year wise Impact Score (IS) of Endocrine, Metabolic and Immune Disorders - Drug Targets

Impact Score Table

Year Impact Score (IS)
2022/2023 Coming Soon
2021 2.31
2020 2.68
2019 1.97
2018 1.27
2017 2.02
2016 2.23
2015 2.04
2014 1.77



Top Journals/Conferences in Endocrinology, Diabetes and Metabolism

Lancet Diabetes and Endocrinology,The
Elsevier BV | Netherlands

Nature Reviews Endocrinology
Nature Publishing Group | United Kingdom

Diabetes Care
American Diabetes Association Inc. | United States

Endocrine Reviews
The Endocrine Society | United States

Nature Metabolism
Springer Berlin | Germany

Trends in Endocrinology and Metabolism
Elsevier Inc. | United States

Diabetologia
Springer Verlag | Germany

Bone Research
Nature Publishing Group | United Kingdom

Diabetes
American Diabetes Association Inc. | United States

Obesity Reviews
Wiley-Blackwell Publishing Ltd | United Kingdom

See All

Top Journals/Conferences in Immunology and Allergy

Nature Reviews Immunology
Nature Publishing Group | United Kingdom

Annual Review of Immunology
Annual Reviews Inc. | United States

Immunity
Cell Press | United States

Nature Immunology
Nature Publishing Group | United Kingdom

Science immunology
American Association for the Advancement of Science | United States

Journal of Experimental Medicine
Rockefeller University Press | United States

Immunological Reviews
Wiley-Blackwell Publishing Ltd | United Kingdom

Trends in Immunology
Elsevier Ltd. | United Kingdom

Annals of the Rheumatic Diseases
BMJ Publishing Group | United Kingdom

Journal for ImmunoTherapy of Cancer
BioMed Central Ltd. | United Kingdom

See All